Skip to main content

OrbiMed Advisors LLC's Form 4 filing

Corvus Pharmaceuticals, Inc. (CRVS) · filed Jul 1, 2025

Accession no.
0000947871-25-000636
Filed
Jul 1, 2025, 9:23 PM ET
Trade date
Jun 27, 2025
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $4.89M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
OrbiMed Advisors LLCCIK 0001055951Director, 10% Owner
OrbiMed Capital GP V LLCCIK 0001615374Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 27, 2025Common StockXIn-the-money exerciseAcquired+1,397,684$3.50+$4,891,8948,341,338IndirectDuplicate filing
Jun 27, 2025Common StockSSaleDisposed−1,176,332$4.16−$4,891,894.267,165,006Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 27, 2025Common StockXIn-the-money exerciseDisposed−1,397,684$0.00$00IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)